Literature DB >> 23183579

Immunology: Evolving superkines for selectivity.

Shane Miersch, Sachdev S Sidhu.   

Abstract

Mesh：

Substances：

Year:  2012        PMID： 23183579     DOI： 10.1038/nchembio.1119

Source DB:  PubMed          Journal:  Nat Chem Biol        ISSN： 1552-4450            Impact factor:   15.040


× No keyword cloud information.
  11 in total

1.  Acute gastric mucosal injury associated with the systemic administration of interleukin-4.

Authors:  J T Rubin; M T Lotze
Journal:  Surgery       Date:  1992-03       Impact factor: 3.982

Review 2.  Cytokine therapy.

Authors:  Antony Cutler; Frank Brombacher
Journal:  Ann N Y Acad Sci       Date:  2005-11       Impact factor: 5.691

3.  Gene expression profile in interleukin-4-stimulated human vascular endothelial cells.

Authors:  Yong Woo Lee; Sung Yong Eum; Kuey Chu Chen; Bernhard Hennig; Michal Toborek
Journal:  Mol Med       Date:  2004 Jan-Jun       Impact factor: 6.354

4.  Tolerability of adjuvant high-dose interferon alfa-2b: 1 month versus 1 year--a Hellenic Cooperative Oncology Group study.

Authors:  Helen Gogas; Dimitrios Bafaloukos; John Ioannovich; Dimosthenis Skarlos; Aris Polyzos; George Fountzilas; Haralambos P Kalofonos; Gerassimos Aravantinos; Dimosthenis Tsoutsos; Petros Panagiotou; Konstantina Frangia; Theodora Petrakopoulou; Dimitrios Pectasides
Journal:  Anticancer Res       Date:  2004 May-Jun       Impact factor: 2.480

5.  Recombinant human interleukin-4 (rhu IL-4) administered by the intravenous and subcutaneous routes in patients with advanced cancer--a phase I toxicity study and pharmacokinetic analysis.

Authors:  J Prendiville; N Thatcher; M Lind; R McIntosh; A Ghosh; P Stern; D Crowther
Journal:  Eur J Cancer       Date:  1993       Impact factor: 9.162

6.  An immune cell-selective interleukin 4 agonist.

Authors:  A B Shanafelt; C P Forte; J J Kasper; L Sanchez-Pescador; M Wetzel; R Gundel; J M Greve
Journal:  Proc Natl Acad Sci U S A       Date:  1998-08-04       Impact factor: 11.205

7.  Subcutaneous interleukin-4 (IL-4) for relapsed and resistant non-Hodgkin lymphoma: a phase II trial in the North Central Cancer Treatment Group, NCCTG 91-78-51.

Authors:  David M Kurtz; Loren K Tschetter; Jacob B Allred; Susan M Geyer; Paul J Kurtin; Wesley D Putnam; Kendrith M Rowland; Martin Wiesenfeld; Gamini S Soori; Richard C Tenglin; Albert M Bernath; Thomas E Witzig
Journal:  Leuk Lymphoma       Date:  2007-07

8.  Receptors for interleukin (IL)-4 do not associate with the common gamma chain, and IL-4 induces the phosphorylation of JAK2 tyrosine kinase in human colon carcinoma cells.

Authors:  T Murata; P D Noguchi; R K Puri
Journal:  J Biol Chem       Date:  1995-12-22       Impact factor: 5.157

9.  The receptor for type I IFNs is highly expressed on peripheral blood B cells and monocytes and mediates a distinct profile of differentiation and activation of these cells.

Authors:  Sarah L Pogue; Benjamin T Preston; Joseph Stalder; Christopher R Bebbington; Pina M Cardarelli
Journal:  J Interferon Cytokine Res       Date:  2004-02       Impact factor: 2.607

10.  Redirecting cell-type specific cytokine responses with engineered interleukin-4 superkines.

Authors:  Ilkka S Junttila; Remi J Creusot; Ignacio Moraga; Darren L Bates; Michael T Wong; Michael N Alonso; Megan M Suhoski; Patrick Lupardus; Martin Meier-Schellersheim; Edgar G Engleman; Paul J Utz; C Garrison Fathman; William E Paul; K Christopher Garcia
Journal:  Nat Chem Biol       Date:  2012-10-28       Impact factor: 15.040
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.